Teva’s bid to combine with the generic-drug business of Allergan would vault the Israeli company into the top ranks of global drug makers and further a remodeling of the industry by a few players that were relatively unknown just a few years ago.
WSJ.com: Markets, Wall Street Journal: Markets: Market News
Sun, 07/26/2015 - 5:09pm
Teva’s bid to combine with the generic-drug business of Allergan would vault the Israeli company into the top ranks of global drug makers and further a remodeling of the industry by a few players that were relatively unknown just a few years ago.